Under the terms of the agreement, THB will manage Nexelis' biospecimen procurement activities, consolidating Nexelis' current sourcing channels with those of THB spanning over 20 countries worldwide.
With unrivaled expertise in immunology, and operating sites in North America (East and West Coast) and Europe, Nexelis is a provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields.
Our versatile team of scientists, working with our advanced technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines, anti-viral drugs, and immunotherapy, gene and cell therapy products.
Trans-Hit Biomarkers Inc is a worldwide biospecimen procurement CRO with the most extensive collection capability for biospecimens and clinical samples through an unrivalled worldwide partnered network of clinical partners and biobanks.
The company, led by a team with a solid background in biomedical research, advises and provides biopharma and diagnostic clients with the best solutions to help design, organize, and conduct sample collections in various fields including oncology, infectious and CNS diseases, among others.
THB manages the entire biospecimen acquisition process, from the initial sample request, to the moment the samples are delivered, and beyond. To learn more about THB, please, visit www.trans-hit.com.
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development